Ask AI
Immunotherapy and Novel Targeted Therapies in SCLC

CE / CME

Mastering the Evolving Treatment Paradigm in SCLC: Expert Case Discussions to Aid Integration of Immunotherapy and Novel Targeted Therapies

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Released: June 23, 2025

Expiration: December 22, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Patient Case 1: Treatment for LS-SCLC



  • 62-yr-old woman presents with chest pain and shortness of breath, ECOG PS 1

  • Chest X-ray: R hilar mass

  • Chest CT: 3.4 cm RUL mass, 3 cm R hilar node

  • PET/CT: positive only in RUL and R hilar mass

  • Brain MRI: negative

  • EBUS-guided biopsy: small cell from RUL mass and subcarinal node

  • She undergoes concurrent CRT (cisplatin/etoposide and thoracic radiotherapy 70 Gy QD) with a good partial response and no significant toxicity


   

What is the most appropriate next step for this patient’s treatment plan?

2.

Patient Case 2: Relapsed ES-SCLC After Initial Response to First-line Therapy



  • 56-yr-old patient with a history of COPD, diagnosed with ES-SCLC 6 mo prior 

  • Received first-line therapy with etoposide, carboplatin, and durvalumab x 4 cycles followed by durvalumab maintenance for 3 mo

  • PET after cycle 3 of maintenance durvalumab showed PD with new LN, chest wall and liver metastases

  • MRI shows 2 sub-cm asymptomatic brain mets

  • PS 0; labs adequate; no symptoms


   

Which of the following systemic treatment options would you select for this platinum-refractory patient?

3.

For a patient with recurrent SCLC receiving a DLL3 x CD3 bispecific antibody with grade 2 CRS with fever and hypotension, which of the following initial management steps would you recommend?

4.

Which of the following outcomes was reported from the phase II IDeate-Lung01 trial evaluating ifinatamab deruxtecan (I-DXd) in patients with previously treated extensive-stage SCLC (ES-SCLC)?